ARTICLE | Clinical News
Intercept Plasma System: Phase III
August 20, 2001 7:00 AM UTC
In a double-blind Phase III study comparing Intercept Platelets to control platelets in 671 patients with severe thrombocytopenia, CERS said the product met its primary endpoint of a statistically equ...